1-15 of 15
Remus Vezan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101

Free
Marc Hoffmann, Shuo Ma, Herbert Eradat, Constantine Tam, Masa Lasica, Paul Hampel, Emma Verner, Lori Leslie, Christopher D'Angelo, Jacob Soumerai, Mazyar Shadman, Chan Cheah, Monica Tani, Yiqian Fang, Binghao Wu, Gabriel Man, Sheel Patel, Remus Vezan, Stephen Opat
Journal: Blood
Blood (2025) 146 (Supplement 1): 793.
https://doi.org/10.1182/blood-2025-793
Published: 2025
Journal Articles

A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL)

Free
Talha Munir, Leyla Mohseninejad, Sheng Xu, Keri Yang, Rhys Williams, Remus Vezan, Nicolas Martinez-Calle
Journal: Blood
Blood (2025) 146 (Supplement 1): 7436.
https://doi.org/10.1182/blood-2025-7436
Published: 2025
Journal Articles

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

Free
Constantine Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, James Hilger, Remus Vezan, Chan Cheah
Journal: Blood
Blood (2025) 146 (Supplement 1): 3891.
https://doi.org/10.1182/blood-2025-3891
Published: 2025
Journal Articles

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101

Free
Jacob Soumerai, Stephen Opat, Chan Cheah, Mazyar Shadman, Emma Verner, Monica Tani, Marc Hoffmann, Lori Leslie, Shuo Ma, Yiqian Fang, Gabriel Man, Binghao Wu, Charity Henrich, Sheel Patel, Remus Vezan, Constantine Tam
Journal: Blood
Blood (2025) 146 (Supplement 1): 3890.
https://doi.org/10.1182/blood-2025-3890
Published: 2025
Journal Articles

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Free
Shuhua Yi, Keshu Zhou, Ning Liu, Wei Sang, Rui Huang, Yi Wang, Chenghui Zhang, Fudao Wu, Ying Li, Mei Sun, Jian-Qing Mi, Kaiyang Ding, Sujun Gao, Qiaohua Zhang, Haiying Hua, Xiaoxia Chu, Jian Cheng, Aikebaier Abudureyimu, Lanyun Zhou, Cheryl Chow, Tianlei Chen, Zhiyu Liang, Remus Vezan, Lugui Qiu
Journal: Blood
Blood (2025) 146 (Supplement 1): 5666.
https://doi.org/10.1182/blood-2025-5666
Published: 2025
Journal Articles

Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study

Free
Michael Wang, Yuqin Song, Olivier Hermine, Yuerong Shuang, Wojciech Jurczak, João Samuel de Holanda Farias, Carolina Mahuad, Muhit Ozcan, Ron D. Jachimowicz, Tianlei Chen, Elena Ivanova, Xiaotong Li, Gabriel Man, Priscille Bourquelot, Remus Vezan, Toby Eyre
Journal: Blood
Blood (2025) 146 (Supplement 1): 663.
https://doi.org/10.1182/blood-2025-663
Published: 2025
Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Free
Othman Al-Sawaf, Sandra Robrecht, Matthew S Davids, Mary Ann Anderson, Romain Guieze, Valeria Buccheri, Celso Arrais-Rodrigues, Francesc Bosch Albareda, Ruth Clifford, Michael Doubek, Krzysztof Jamroziak, Arnon Kater, Mattias Mattsson, Carsten Niemann, Miguel Pavlovsky, Lydia Scarfo, Renata Walewska, Peng Liu, Ki-Seong Eom, Karl Kreuzer, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Kenneth Wu, Marcus Lefebure, Wei Ding, Remus Vezan, Barbara Eichhorst
Journal: Blood
Blood (2025) 146 (Supplement 1): 2137.
https://doi.org/10.1182/blood-2025-2137
Published: 2025
Journal Articles

Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Free
Judith Trotman, Katherine Rankin, Ibrahim Tohidi-Esfahani, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G Owen, Veronique LeBlond, Meletios A. Dimopoulos, Peter Smallwood, Heather Allewelt, Wai Y Chan, Radha Prathikanti, Jingjing Schneider, Remus Vezan, Stephen S. Opat
Journal: Blood
Blood (2024) 144 (Supplement 1): 4412.
https://doi.org/10.1182/blood-2024-200334
Published: 2024
Journal Articles

Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study

Free
Constantine S. Tam, Stephen S. Opat, Eileen Grace Merriman, Jan A. Burger, Emma Verner, Paula Marlton, David Gottlieb, Ian W. Flinn, Sumit Madan, Matthew Ku, Radha Prathikanti, Heather Allewelt, Tian Tian, Remus Vezan, Gavin Cull
Journal: Blood
Blood (2024) 144 (Supplement 1): 3255.
https://doi.org/10.1182/blood-2024-200363
Published: 2024
Journal Articles

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Free
Shirley D'Sa, Meletios A. Dimopoulos, Wojciech Jurczak, Paula Marlton, Stephen P. Mulligan, Bjorn E Wahlin, Magdalena Sobieraj-Teague, Andrew W. Roberts, Constantine S. Tam, Jorge J. Castillo, Heather Allewelt, Radha Prathikanti, Wai Y Chan, Tian Tian, Jingjing Schneider, Remus Vezan, Stephen S. Opat
Journal: Blood
Blood (2024) 144 (Supplement 1): 3031.
https://doi.org/10.1182/blood-2024-199276
Published: 2024
Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Free
Clinical Trials & Observations
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O’Dwyer, Houston Holmes, Martha L. Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda
Journal: Blood
Blood (2021) 138 (1): 11–22.
https://doi.org/10.1182/blood.2020009098
Published: 2021
Includes: Supplemental data
Journal Articles

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Free
Caron Jacobson, MD MMSc, Julio C. Chavez, MD, Alison R. Sehgal, MD, Basem M. William, MDMRCP, Javier Munoz, MD, Gilles Salles, MDPhD, Pashna N. Munshi, MD, Carla Casulo, MD, David Maloney, MD PhD, Sven de Vos, MD PhD, Ran Reshef, MD, Lori A. Leslie, MD, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, MBBS, MPH, Henry C.H. Fung, MD, Joseph D. Rosenblatt, MD, John M. Rossi, MS, Lovely Goyal, PhD, Vicki Plaks, LLB, PhD, Yin Yang, MS, Jennifer Lee, BS, Wayne Godfrey, MD, Remus Vezan, MD PhD, Mauro P. Avanzi, MD PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-136834
Published: 2020
Journal Articles

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Free
Caron Jacobson, MD MMSc, Frederick L. Locke, MD, Armin Ghobadi, MD, David B. Miklos, MD PhD, Lazaros J. Lekakis, MD, Olalekan O. Oluwole, MBBS, MPH, Yi Lin, MD PhD, Ira Braunschweig, MD, Brian T. Hill, MD, John M. Timmerman, MD, Abhinav Deol, MD, Patrick M. Reagan, MD, Patrick J. Stiff, MD, Ian W. Flinn, MD PhD, Umar Farooq, MD, Andre H. Goy, MD, Peter A. McSweeney, MD, Javier Munoz, MD, Tanya Siddiqi, MD, John M. Rossi, MS, Adrian Bot, MD PhD, Lianqing Zheng, PhD, Remus Vezan, MD PhD, Zahid Bashir, MBBS, Jenny J. Kim, MD MS, Rong Chu, PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-134362
Published: 2020
Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Free
Clinical Trials & Observations
John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James, Jennifer R. Brown
Journal: Blood
Blood (2019) 133 (19): 2031–2042.
https://doi.org/10.1182/blood-2018-08-870238
Published: 2019
Includes: Supplemental data
Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Free
William G. Wierda, MD PhD, Michael R. Bishop, MD, Olalekan O. Oluwole, MBBS, MPH, Aaron C. Logan, MD PhD, Maria R. Baer, MD, William B. Donnellan, MD, Kristen M. O'Dwyer, MD, Januario E. Castro, MD, Gary J. Schiller, MD, Houston Holmes, MD, Mehrdad Abedi, MD, Armin Ghobadi, MD, Martha L. Arellano, MD, Adriana K. Malone, MD, John M. Pagel, MD PhD, Armen Mardiros, PhD, Tong Shen, MS, Remus Vezan, MD PhD, Rajul K. Jain, MD, Bijal D. Shah, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 897.
https://doi.org/10.1182/blood-2018-99-111531
Published: 2018